Difference between revisions of "Thrombocytopenia in liver disease"
Jump to navigation
Jump to search
(→Regimen ) Tag: visualeditor-switched |
|||
| Line 23: | Line 23: | ||
|} | |} | ||
===Regimen {{#subobject:666055|Variant=1}}=== | ===Regimen {{#subobject:666055|Variant=1}}=== | ||
| − | {| class="wikitable" | + | {| class="wikitable" style="color:white; background-color:#404040" |
| + | |<small>'''FDA-recommended dose'''</small> | ||
|- | |- | ||
| − | ! Study ! | + | |} |
| + | {| class="wikitable" style="width: 100%; text-align:center;" | ||
| + | !Study | ||
| + | ![[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !Comparator | ||
| + | ![[Levels_of_Evidence#Efficacy|Efficacy]] | ||
|- | |- | ||
| − | | [https://www. | + | |[https://www.sciencedirect.com/science/article/pii/S0016508518345451 Terrault et al. 2018 (ADAPT-1/ADAPT-2)] |
| + | | style="background-color:#1a9851" |Phase III (E) | ||
| + | |Placebo | ||
| + | | style="background-color:#1a9850" |Superior primary endpoint | ||
|- | |- | ||
| − | |||
|} | |} | ||
====Therapy==== | ====Therapy==== | ||
| Line 37: | Line 45: | ||
'''Procedure days were days 10 to 13''' | '''Procedure days were days 10 to 13''' | ||
| + | ===References=== | ||
| + | # Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 May 17. [Epub ahead of print] [https://www.sciencedirect.com/science/article/pii/S0016508518345451 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/29778606 PubMed] | ||
[[Category:Thrombocytopenia in liver disease regimens]] | [[Category:Thrombocytopenia in liver disease regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Cytopenias]] | [[Category:Cytopenias]] | ||
Revision as of 20:21, 24 May 2018
| Section editors | |||
|---|---|---|---|
 |
Shruti Chaturvedi, MBBS, MSCI Baltimore, MD |
 |
Benjamin Tillman, MD Nashville, TN |
See the thrombocytopenia reference page for general definitions and workup recommendations.
2 regimens on this page
2 variants on this page
|
Thrombocytopenia in liver disease with planned procedure
Avatrombopag monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| Terrault et al. 2018 (ADAPT-1/ADAPT-2) | Phase III (E) | Placebo | Superior primary endpoint |
Therapy
- Avatrombopag (Doptelet) as follows:
- Platelet count less than 40 x 109/L: 60 mg PO once per day on days 1 to 5
- Platelet count at least 40 and less than 50 x 109/L: 40 mg PO once per day on days 1 to 5
Procedure days were days 10 to 13
References
- Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018 May 17. [Epub ahead of print] link to SD article PubMed